Yingke Medical Technology Co., Ltd. (referred to as Yingke Medical) is a high-tech manufacturing enterprise dedicated to the research and development, production, and marketing of medical device consumables. It was listed on the ChiNext board of the Shenzhen Stock Exchange in July 2017, with stock code 300677. It is one of the top 500 Chinese brands, one of the top 500 manufacturing enterprises in China, and one of the top 100 listed companies in 2021. Our business covers a series of products including medical consumables, health equipment, and physical therapy nursing. The product is widely used in medical institutions, elderly care institutions, household daily necessities, and other related industries. Yingke Medical products have been exported to over 120 countries and regions in the Americas, Europe, Asia, Africa, and Oceania, providing practical products and high-quality services to over 10000 customers worldwide.

WuXi AppTec (stock code: 603259.SH/2359. HK) provides integrated, end-to-end new drug research and production services for the global biopharmaceutical industry, with operating bases in Asia, Europe, North America, and other regions. Through its unique "CRDMO" and "CTDMO" business models, WuXi AppTec continuously lowers research and development thresholds, helps customers improve research and development efficiency, and brings more breakthrough treatment plans to patients. Its service scope covers chemical drug research and production, biological research, preclinical testing and clinical trial research and development, cell and gene therapy research and development, testing and production, and other fields. In 2023, WuXi AppTec was rated as ESG (Environmental, Social, and Governance) AA by MSCI. At present, the company's empowerment platform is carrying R&D innovation projects from over 6000 partners from more than 30 countries around the world, committed to bringing more new and good drugs to patients worldwide, and realizing the vision of "making the world without difficult drugs and difficult diseases" as soon as possible.

Hengrui Pharmaceutical was founded in 1970 and listed on the Shanghai Stock Exchange in 2000. It is an innovative international pharmaceutical enterprise that focuses on the research and development, production, and promotion of high-quality drugs. It focuses on the research and development of new drugs in fields such as anti-tumor, metabolic diseases, autoimmune diseases, respiratory diseases, and neurological diseases. It is one of the most innovative pharmaceutical leading enterprises in China. For more than 50 years, Hengrui Pharmaceutical has always adhered to the original intention of serving patients, worked hard to protect the healthy life and quality of life of patients, overcome difficulties, and promote the high-quality development of the pharmaceutical industry. Hengrui Pharmaceuticals has been on the top 50 global pharmaceutical companies list published by the American Journal of Pharmaceutical Managers for five consecutive years; In the "Top 25 Global Pharmaceutical Enterprise R&D Pipeline Scale" list selected by the global pharmaceutical think tank information platform Informa Pharma Intelligence, Hengrui Pharmaceutical ranks 13th, setting a new high for Chinese pharmaceutical companies on this list; The China Pharmaceutical Industry Information Center has released the "Best Industrial Enterprise in China's Pharmaceutical R&D Product Line" over the years, and Hengrui Pharmaceutical has topped the list 11 times.

Nanjing Tianyinshan Hospital was approved for construction at the end of 2019 and has been included in the major project plans of Jiangsu Province and Nanjing City's economic and social development multiple times. On April 7, 2020, the construction officially began and the first support pile was laid; On June 25, 2021, the main structure of the hospital building was capped and entered the internal decoration phase. On January 4, 2022, it was approved by the Jiangsu Provincial Health Commission for the establishment of a "Level III Cancer Hospital" medical institution; On February 15, 2022, it was included in the "Third level Hospital" directory of the "14th Five Year Plan" for the establishment of medical institutions in Nanjing. At the end of October 2023, it passed the planning changes, completion verification, and fire safety acceptance organized by relevant departments of the municipal and district governments. In early December, it passed the medical acceptance and on-site inspection organized by the provincial and municipal health commissions, and has obtained the Medical Practice License. It will open for operation on December 22.

WuXi AppTec (stock code: 603259.SH/2359. HK) provides integrated, end-to-end new drug research and production services for the global biopharmaceutical industry, with operating bases in Asia, Europe, North America, and other regions. Through its unique "CRDMO" and "CTDMO" business models, WuXi AppTec continuously lowers research and development thresholds, helps customers improve research and development efficiency, and brings more breakthrough treatment plans to patients. Its service scope covers chemical drug research and production, biological research, preclinical testing and clinical trial research and development, cell and gene therapy research and development, testing and production, and other fields. In 2023, WuXi AppTec was rated as ESG (Environmental, Social, and Governance) AA by MSCI. At present, the company's empowerment platform is carrying R&D innovation projects from over 6000 partners from more than 30 countries around the world, committed to bringing more new and good drugs to patients worldwide, and realizing the vision of "making the world without difficult drugs and difficult diseases" as soon as possible.

Hubei Zhongxun Changqing Technology Co., Ltd. was established in October 2015, funded by Guangdong Zhongxun Agricultural Science Co., Ltd. The company is committed to the research and production of bio fermentation synthetic pharmaceutical intermediates, environmentally friendly and efficient agricultural products, and their extended products. The registered capital of the company is 50 million yuan. The company is located at No. 28 Jinghe Avenue, Chemical Recycling Industrial Park, Duodao District, High tech Zone, Jingmen City, Hubei Province (at the intersection of Jinghe Avenue and Yangguang Fourth Road), with convenient transportation and beautiful environment. The company has always adhered to the concept of "harmonious coexistence between people and the environment, creating value for users", relying on the reputation and comprehensive strength of the parent company in the industry, and rapidly developing and growing to serve China's rapidly growing green agriculture, rural areas, and farmers industry.